Q-omics provides the consensus-scored TRIM51CP profile across patient tissues and cancer cell-line models. TRIM51CP expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRIM51CP is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, TRIM51CP RNA expression shows 7,741 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, BRCA, and TGCT as cancer lineages where TRIM51CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM51CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM51CP survival associations across molecular data types. TRIM51CP RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM51CP RNA expression–survival associations across cancer types. High TRIM51CP expression shows unfavorable associations in ACC, KIRC, KIRP, DLBC and CESC, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRIM51CP RNA expression.
This table summarizes TRIM51CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM51CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM51CP shows lower tumor expression in BRCA. The BRCA box plot shows higher TRIM51CP RNA expression in normal versus tumor tissue (log2 FC = −0.005, t-test p = .047).
This table shows molecular features associated with TRIM51CP in patient tissues and cancer cell lines. In patient samples, TRIM51CP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
